Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PCAS Interim / Quarterly Report 2012

Oct 16, 2012

1590_iss_2012-10-16_3439de1b-fcaf-47b3-b9c3-bab34b70ef4c.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

QUARTERLY FINANCIAL INFORMATION AT SEPTEMBER 30TH, 2012

Longjumeau, October 16 th, 2012

Net sales up 7% at September 30th, 2012

(in thousands of euros) 2011 2012 % change
First Quarter 44,053 42,728 - 3.0%
including Pharmaceutical Synthesis 27,147 25,454 - 6.2%
including Fine Speciality Chemicals 16,906 17,274 + 2.2%
Second Quarter 41,789 46,633 + 11.6%
including Pharmaceutical Synthesis 26,457 29,910 + 13.1%
including Fine Speciality Chemicals 15,332 16,723 + 9.1%
Third Quarter 33,481 38,355 + 14.6%
including Pharmaceutical Synthesis 19,530 23,298 + 19.3%
including Fine Speciality Chemicals 13,951 15,057 + 7.9%
Total as of 30 September 119,323 127,716 + 7.0%
including Pharmaceutical Synthesis 73,134 78,662 + 7.6%
including Fine Speciality Chemicals 46,189 49,054 + 6.2%

Following a stronger level of business during the third quarter of 2012 compared with the same period in 2011, the PCAS Group's net sales are up 7.0% at September 30th, 2012.

Pharmaceutical Synthesis

Net sales for the third quarter of 2012 came in 19.3% higher than the third quarter of 2011, reflecting the exceptionally concentrated volume of deliveries over this period in 2012.

Fine Specialty Chemicals

The Fine Specialty Chemicals business has continued to grow (+7.9% in the third quarter of 2012 versus the third quarter of 2011), despite the Fragrance business underperforming.

Compared with 2011, fourth-quarter net sales are expected to see significant growth on Pharmaceutical Synthesis, although without reaching the third quarter's exceptional rate of growth. For Fine Specialty Chemicals, the overall level of business looks set to be stable in the fourth quarter.

On the whole, net sales growth in 2012 is expected to closely follow the trend observed at the end of September 2012.

About PCAS :

Founded in 1962, PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.